Ocular Therapeutix (OCUL)
Develops hydrogel-delivered retinal therapies and commercial ophthalmic drug inserts.
$9.94
vs last close−0.56 (−5.33%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 95.04% | 208.73M shares | |
|---|---|---|---|
| 277 holders · as of Jun 30, 2026 | |||
| Insiders | 1.71% | 3.76M shares | |
| 17 holders · as of Sep 2, 2026 | |||
| Other | 3.25% | 7.13M shares | |
| remainder | |||
219.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
277 holders · 208.73M shares · 35 new positions · 140 increased · 82 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 32.84M | 14.96% | +190.3K | Aug 13, 2026 |
| Deep Track Capital, LP | 19.69M | 8.96% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 19.38M | 8.82% | +3.24M | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 12.54M | 5.71% | +225.0K | Aug 14, 2026 |
| Summer Road LLC | 12.21M | 5.56% | +328.5K | Aug 10, 2026 |
| VR Adviser, LLC | 10.35M | 4.71% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 8.83M | 4.02% | +113.6K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 7.62M | 3.47% | +1.73M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 31.79M | 13G | Nov 5, 2025 |
| Deep Track Capital, LP | 9.53% | 20.85M | 13G | May 15, 2026 |
| Avoro Capital Advisors LLCincl. Behzad Aghazadeh | 7.90% | 12.71M | 13G | Nov 14, 2024 |
| BlackRock, Inc. | 5.80% | 10.17M | 13G | Oct 17, 2025 |
| Summer Road LLC | 5.70% | 12.13M | 13G | Dec 8, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Donald Notmanofficer: Chief Operating Officer | Sale | 1,099 | $10.24 | 366,529 |
| Aug 24, 2026 | Jeffrey S. Heierofficer: Chief Scientific Officer | Sale | 3,296 | $10.78 | 318,326 |
| Aug 24, 2026 | Sanjay Nayakofficer: Chief Strategy Officer | Sale | 1,897 | $10.78 | 326,898 |
| Aug 24, 2026 | Peter Kaiserofficer: Chief Development Officer | Sale | 3,035 | $10.77 | 264,378 |
| Aug 24, 2026 | Pravin Dugeldirector, officer: See Remarks | Sale | 21,649 | $10.77 | 2,525,429 |
| Jun 3, 2026 | Nadia Waheedofficer: Chief Medical Officer | Sale | 14,828 | $8.27 | 300,079 |
| May 26, 2026 | Sanjay Nayakofficer: Chief Strategy Officer | Sale | 1,858 | $8.20 | 328,795 |
| May 26, 2026 | Jeffrey S. Heierofficer: Chief Scientific Officer | Sale | 3,018 | $8.20 | 320,350 |
| May 26, 2026 | Peter Kaiserofficer: Chief Development Officer | Sale | 2,967 | $8.20 | 266,141 |
| May 26, 2026 | Pravin Dugeldirector, officer: See Remarks | Sale | 21,156 | $8.20 | 2,597,170 |
House and Senate disclosures
Not reported.